Hong Jae Chon, Director of Cancer Center, CHA Bundang Medical Center, shared on X։
“Our study is now published in Liver International.
Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study
- Nivolumab + ipilimumab showed meaningful and durable activity even after Atezo/Bev failure in a large real-world, multicenter cohort.
- irAEs may signal benefit.
Figure 2C. PFS of Nivo/Ipi responders according to prior Ate/Bev exposure.
Among responders, progression-free survival with nivolumab plus ipilimumab was comparable regardless of prior atezolizumab/bevacizumab exposure, supporting durable clinical benefit in a subset after Ate/Bev failure.
Is 1L immunotherapy failure in advanced HCC complete immune refractoriness?
No-it’s a dynamic shift in escape pathways!
A new Liver International editorial spotlights our study (Kim et al.) on sequential Nivo/Ipi as a rational ‘second chance‘.
Our Key Results:
- 20% ORR in Ate/Bev-experienced patients.
- Durable benefit: 23.7 mo median DoR compared to treatment-naïve cohorts (24.8 mo).
- High TMB and thyroid irAEs predict better survival.
The Editorial’s Key Takeaways:
- Resistance as a ‘Shift‘: Progression is a transition to alternative escape pathways. Complementary dual blockade (PD-1 + CTLA-4) can successfully re-engage T cells.
- Our biomarker data provides a roadmap to shift HCC sequencing from empirical trial-and-error to precision oncology.
Title: Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study
Authors: Jung Sun Kim, Jeffrey Wong, San-Chi Chen, David Tai, Hannah Yang, Youngun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Chansik An, Su Jin Jang, Masatoshi Kudo, Ho Yeong Lim, Chan Kim, Thomas Yau, Hong Jae Chon
Other articles about HCC on OncoDaily.